Cargando…
Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib
[Image: see text] Olaparib (Lynparza) is a potent, highly selective inhibitor of poly(ADP-ribose)polymerase enzymes, approved by the U.S. FDA and EMA for the treatment of ovarian cancer. Herein, we report a practical, economical, and scalable process for the synthesis of 2-fluoro-5-((4-oxo-3,4-dihyd...
Autores principales: | Chen, Zhaohang, Wang, Shuai, Liu, Kangjie, Zhang, Rui, Li, Qiaoying, Bian, Weiguang, Qiao, Renzhong, Li, Chao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867798/ https://www.ncbi.nlm.nih.gov/pubmed/35224393 http://dx.doi.org/10.1021/acsomega.1c06920 |
Ejemplares similares
-
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
por: Faraoni, Isabella, et al.
Publicado: (2019) -
Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice
por: Liu, Wei, et al.
Publicado: (2020) -
RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015) -
Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019) -
The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)